WVE Stock Analysis: Wave Life Sciences | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 1.066m USD | 12M Return: -45.8% | SG9999014716 | Charts, Fundamentals & Technical Analysis

RNA Editing, RNA Interference, Antisense Oligonucleotides, Genetic Medicines
Total Rating 12
Safety 37
Buy Signal -1.06
Biotechnology
Industry Rotation: +3.6
Market Cap: 1.07B
Avg Turnover: 16.8M
Risk 3d forecast
Volatility82.8%
VaR 5th Pctl12.6%
VaR vs Median-5.78%
Reward TTM
Sharpe Ratio0.19
Rel. Str. IBD1.1
Rel. Str. Peer Group3
Character TTM
Beta2.236
Beta Downside2.197
Hurst Exponent0.445
Drawdowns 3y
Max DD76.30%
CAGR/Max DD0.05
CAGR/Mean DD0.11
EPS (Earnings per Share) EPS (Earnings per Share) of WVE over the last years for every Quarter: "2021-06": -0.78, "2021-09": -0.12, "2021-12": -0.61, "2022-03": -0.62, "2022-06": -0.62, "2022-09": -0.42, "2022-12": -0.47, "2023-03": -0.27, "2023-06": -0.2, "2023-09": 0.07, "2023-12": -0.15, "2024-03": -0.24, "2024-06": -0.25, "2024-09": -0.47, "2024-12": 0.17, "2025-03": -0.29, "2025-06": -0.31, "2025-09": -0.32, "2025-12": -0.3, "2026-03": -0.13, "2026-06": -0.34,
Last SUE: -0.19
Qual. Beats: 0
Revenue Revenue of WVE over the last years for every Quarter: 2021-06: 2.776, 2021-09: 36.423, 2021-12: 1.765, 2022-03: 1.75, 2022-06: 0.375, 2022-09: 0.285, 2022-12: 1.239, 2023-03: 12.929, 2023-06: 22.106, 2023-09: 49.214, 2023-12: 29.056, 2024-03: 12.538, 2024-06: 19.692, 2024-09: -7.676, 2024-12: 83.748, 2025-03: 9.175, 2025-06: 8.699, 2025-09: 7.608, 2025-12: 17.245, 2026-03: 38.246, 2026-06: 2.272,
Rev. CAGR: -15.76%
Rev. Trend: -47.0%
Last SUE: -0.20
Qual. Beats: 0

Warnings

Strong Share Dilution
Altman Z'' In Financial Distress Zone
Below Avwap Earnings
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 10.7 years of data

Jan -10.7% 45
Feb +9.3% 15
Mar -11.8% 27
Apr -5.2% 15
May -4.5% 28
Jun -1.1% 2
Jul +0.3% 5
Aug +16.6% 58
Sep -5.8% 17
Oct +4.4% 9
Nov -0.4% 18
Dec -11.0% 38

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: WVE Wave Life Sciences

Wave Life Sciences Ltd. (NASDAQ: WVE) is a clinical-stage biotechnology company headquartered in Singapore that uses its proprietary PRISM platform to design and develop RNA-based medicines. Its pipeline includes candidates targeting alpha-1 antitrypsin deficiency (WVE-006), obesity (WVE-007), liver disease (WVE-008), Duchenne muscular dystrophy (WVE-N531), and Huntingtons disease (WVE-003). The company operates under a partnership-heavy business model, with collaboration agreements with GlaxoSmithKline, Takeda Pharmaceutical, and Asuragen supporting research, development, and commercialization of its oligonucleotide programs. Founded in 2012 and listed on NASDAQ since 2015, Wave is classified within the GICS Pharmaceuticals sub-industry and currently carries a small-cap market valuation of approximately $1.2 billion.

Headlines to Watch Out For
  • WVE-006 alpha-1 antitrypsin deficiency clinical data readout approaches
  • GSK and Takeda collaborations deliver milestone payments
  • Equity dilution risk as clinical-stage cash burn accelerates
Piotroski VR-10 (Strict) 1.0
Net Income: -202.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.33 > 0.02 and ΔFCF/TA 45.94 > 1.0
NWC/Revenue: 698.6% < 20% (prev 144.9%; Δ 553.7% < -1%)
CFO/TA -0.33 > 3% & CFO -184.7m > Net Income -202.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 9.99 > 1.5 & < 3
Outstanding Shares: last quarter (202.1m) vs 12m ago 23.24% < -2%
Gross Margin: 86.46% > 18% (prev 23.09%; Δ 63.36% > 0.5%)
Asset Turnover: 16.13% > 50% (prev 37.23%; Δ -21.10% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' -1.82
A: 0.82 (Total Current Assets 507.5m - Total Current Liabilities 50.8m) / Total Assets 558.3m
B: -2.55 (Retained Earnings -1.42b / Total Assets 558.3m)
C: -0.51 (EBIT TTM -206.6m / Avg Total Assets 405.3m)
D: 4.33 (Book Value of Equity 453.5m / Total Liabilities 104.8m)
Altman-Z'' = -1.82 = D
Beneish M -4.00
DSRI: 0.79 (Receivables 888k/1.62m, Revenue 65.4m/93.9m)
GMI: 0.27 (GM 23.09% / 86.46%)
AQI: 0.45 (AQ_t 0.01 / AQ_t-1 0.02)
SGI: 0.70 (Revenue 65.4m / 93.9m)
TATA: -0.03 (NI -202.5m - CFO -184.7m) / TA 558.3m)
Beneish M = -4.41 (Cap -4..+1) = AAA
What is the price of WVE shares?

As of August 22, 2026, the stock is trading at USD 5.29 with a total of 2,700,241 shares traded. Over the past week, the price has changed by -2.22%, over one month by -8.64%, over three months by -17.60% and over the past year by -45.80%.

Current recommended Stop Loss: 4.90 (which is 7.4% or 1.2 ATR below the current price).

Is WVE a buy, sell or hold?

Wave Life Sciences has received a consensus analysts rating of 4.62. Therefore, it is recommended to buy WVE.

  • StrongBuy: 9
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the WVE price?
Analysts Target Price 19.1 260.3%
Wave Life Sciences (WVE) - Fundamental Data Overview as of 17 August 2026
Market Cap USD = 1.07b (1.07b USD * 1.0 USD.USD)
P/S = 16.3074
P/B = 2.3527
Revenue TTM = 65.4m USD
EBIT TTM = -206.6m USD
EBITDA TTM = -197.5m USD
Long Term Debt = 40.1m USD (estimated: total debt 43.6m - short term 3.51m)
Short Term Debt = 3.51m USD (from shortTermDebt, last quarter)
Debt = 43.6m USD (from shortLongTermDebtTotal, last quarter) (leases 43.6m already included)
Net Debt = -447.0m USD (calculated: Debt 43.6m - CCE 490.6m)
Enterprise Value = 619.0m USD (1.07b + Debt 43.6m - CCE 490.6m)
 Interest Coverage Ratio = unknown (Ebit TTM -206.6m / Interest Expense TTM 0.0)
 EV/FCF = -3.32x (Enterprise Value 619.0m / FCF TTM -186.2m)
FCF Yield = -30.09% (FCF TTM -186.2m / Enterprise Value 619.0m)
 FCF Margin = -284.9% (FCF TTM -186.2m / Revenue TTM 65.4m)
 Net Margin = -309.7% (Net Income TTM -202.5m / Revenue TTM 65.4m)
 Gross Margin = 86.46% ((Revenue TTM 65.4m - Cost of Revenue TTM 8.85m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.11 (Enterprise Value 619.0m / Total Assets 558.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 43.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -163.2m (EBIT -206.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.99 (Total Current Assets 507.5m / Total Current Liabilities 50.8m)
Debt / Equity = 0.10 (Debt 43.6m / totalStockholderEquity, last quarter 453.5m)
 Debt / EBITDA = 2.26 (negative EBITDA) (Net Debt -447.0m / EBITDA -197.5m)
 Debt / FCF = 2.40 (negative FCF - burning cash) (Net Debt -447.0m / FCF TTM -186.2m)
 Total Stockholder Equity = 404.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -49.95% (Net Income -202.5m / Total Assets 558.3m)
RoE = -50.12% (Net Income TTM -202.5m / Total Stockholder Equity 404.0m)
RoCE = -46.53% (EBIT -206.6m / Capital Employed (Equity 404.0m + L.T.Debt 40.1m))
 RoIC = -32.15% (negative operating profit) (NOPAT -163.2m / Invested Capital 507.7m)
 WACC = 13.31% (E(1.07b)/V(1.11b) * Re(13.85%) + D(43.6m)/V(1.11b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 13.85% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 94.02 | Cagr: 21.97%
 [DCF] Fair Price = unknown (Cash Flow -186.2m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.19 | # QB: 0
Revenue Correlation: -47.00 | Revenue CAGR: -15.76% | SUE: -0.20 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.32 | Chg30d=-3.32% | Revisions=-25% | Analysts=13
EPS current Year (2026-12-31): EPS=-1.11 | Chg30d=-32.44% | Revisions=-50% | GrowthEPS=+8.3% | GrowthRev=+22.4%
EPS next Year (2027-12-31): EPS=-1.19 | Chg30d=-9.84% | Revisions=-17% | GrowthEPS=-7.3% | GrowthRev=-29.2%
[Analyst] Revisions Ratio: -50% (up=1, down=6)